Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Examining Real-World Uptake and Effectiveness of GLP-1 RA in an Urban Population with Type-2 Diabetes

Award Number: F31DK146642
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 03/08/2027
PERIOD OF PERFORMANCE END DATE: 03/07/2028

Group Awards By:

View Award Description

Examining Real-World Uptake and Effectiveness of GLP-1 RA in an Urban Population with Type-2 Diabetes - Project Summary: Type 2 diabetes (T2D) affects nearly 30% of Americans aged 65 and older, with significant variation in treatment quality across healthcare settings. Recent American Diabetes Association (ADA) guidelines recommend GLP-1 receptor agonists (GLP-1 RAs) as preferred second-line agents due to their cardiovascular and weight benefits, but adoption patterns among older adults vary between healthcare settings serving different populations. This research examines differences in GLP-1 RA adoption among older adults with T2D across New York City's (NYC) public and private hospital systems following guideline changes. Aim 1 will analyze the uptake of ADA clinical guideline recommendations on GLP-1 RAs among T2D patients treated in NYC public and private hospitals, by comorbidity status. Aim 2 will use target trial emulation to assess the effect of switching from other second-line T2D medications to GLP-1 RAs on cardiovascular disease risk factors and events, versus continuing on DPP-4 inhibitors, thiazolidinediones, or sulfonylureas. Aim 3 will evaluate the extent to which weight loss mediates effects of GLP-1 RAs on cardiovascular disease risk factors and events using causal mediation analysis. The fellowship provides comprehensive training in (1) mastery of electronic health record (EHR) data structures and query, (2) advanced training in causal inference methods, (3) applications of pharmacoepidemiologic approaches using EHR data, and (4) development of scientific communication skills and career development in clinical epidemiology. The research will be conducted out of NYU Langone Health Grossman School of Medicine and combines resources from two large regional EHR networks: NYC Health + Hospitals, the public hospital system, and the INSIGHT Clinical Research Network, a network of academic medical centers, providing access to robust and distinct patient populations. This project will provide evidence on medication access patterns and comparative effectiveness of T2D treatments in older adults, directly supporting NIDDK’s mission to improve the lives of patients living with this disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $36,947 )
2026	2026	NEW YORK UNIVERSITY	550 1ST AVE	NEW YORK	NY	10016	NEW YORK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	9/17/2026	NEW	$36,947
														Subtotal = $36,947

Grand Total All Awards = $36,947

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Examining Real-World Uptake and Effectiveness of GLP-1 RA in an Urban Population with Type-2 Diabetes

Award Number: F31DK146642

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 03/08/2027

PERIOD OF PERFORMANCE END DATE: 03/07/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer